SCHEMBL24532763

SCHEMBL24532763

CC1CCN(c2ccc3nccc(C(=O)O)c3c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ LMNA P02545 1/20 0.50
▸ GAA P10253 4/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ MITF O75030 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ NFKB2 Q00653 1/20 0.43
▸ RELA Q04206 1/20 0.43
▸ HTT P42858 1/20 0.42
▸ IP6K1 Q92551 1/20 0.41
▸ POLB P06746 2/20 0.40
▸ MEN1 O00255 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29681111 0.93 LMNA (0.48) USP2KMT2ALMNAGAAALDH1A1
SCHEMBL24532478 0.93 LMNA (0.48) USP2KMT2ALMNAGAAALDH1A1
SCHEMBL24532204 0.93 LMNA (0.48) USP2KMT2ALMNAGAAALDH1A1
SCHEMBL24532198 0.93 LMNA (0.48) USP2KMT2ALMNAGAAALDH1A1
SCHEMBL29681272 0.93 LMNA (0.48) USP2KMT2ALMNAGAAALDH1A1
Hydrochloric Acid SCHEMBL29681298 0.92 LMNA (0.47) USP2KMT2ALMNAGAAALDH1A1
Hydrochloric Acid SCHEMBL29681674 0.92 LMNA (0.47) USP2KMT2ALMNAGAAALDH1A1
SCHEMBL29681564 0.89 LMNA (0.48) KMT2ALMNAALDH1A1KDM4EIP6K1
SCHEMBL24532558 0.89 LMNA (0.48) KMT2ALMNAALDH1A1KDM4EIP6K1
SCHEMBL24532150 0.87 LMNA (0.45) USP2KMT2ALMNAGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858924-B2 N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides ASTRAZENECA (SE) 2024-01-02 — — US disclosed
US-20230312550-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES ASTRAZENECA AB (SE) 2023-10-05 — — US disclosed
WO-2022130270-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES ASTRAZENECA AB (SE) 2022-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312550-A1 N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES FAP, PREP, CTRL USP2 1190/4885KMT2A 1862/4885LMNA 938/4885
US-11858924-B2 N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides FAP, PREP, CTRL USP2 1190/4885KMT2A 1862/4885LMNA 938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback